Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms

Molecular Pharmacology

Volumn 77, Issue 4, 2010, Pages 670-677

  Rybalkina, Irina G ^a   Tang, Xiao Bo ^a   Rybalkin, Sergei D ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE; PHOSPHODIESTERASE GAF A; PHOSPHODIESTERASE GAF B; PHOSPHODIESTERASE V; SILDENAFIL; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; CELLS, CULTURED; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HUMANS; MICE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; PURINES; SULFONES;

EID: 77950223491     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.062299     Document Type: Article

References (35)

1. Aravind L and Ponting CP (1997) The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci 22:458-459.
2. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, and Naylor AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159:2164-2171.
3. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, and Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66:144-152.
4. Blount MA, Zoraghi R, Bessay EP, Beasley A, Francis SH, and Corbin JD (2007) Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors. J Pharmacol Exp Ther 323:730-737.
5. Bruder S, Schultz A, and Schultz JE (2006) Characterization of the tandem GAF domain of human phosphodiesterase 5 using a cyanobacterial adenylyl cyclase as a reporter enzyme. J Biol Chem 281:19969-19976.
6. Corbin JD, Blount MA, Weeks JL 2nd, Beasley A, Kuhn KP, Ho YS, Saidi LF, Hurley JH, Kotera J, and Francis SH (2003) [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol Pharmacol 63:1364-1372.
7. Francis SH, Morris GZ, and Corbin JD (2008) Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res 20:333-342.
8. Ghofrani HA, Osterloh IH, and Grimminger F (2006) Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 5:689-702.
9. Gingell C, Sultana SR, Wulff MB, and Gepi-Attee S (2004) Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med 1:179-184.
10. Gopal VK, Francis SH, and Corbin JD (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 268:3304-3312.
11. Handa N, Mizohata E, Kishishita S, Toyama M, Morita S, Uchikubo-Kamo T, Akasaka R, Omori K, Kotera J, Terada T, et al. (2008) Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP. J Biol Chem 283:19657-19664.
12. Heikaus CC, Stout JR, Sekharan MR, Eakin CM, Rajagopal P, Brzovic PS, Beavo JA, and Klevit RE (2008) Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. J Biol Chem 283:22749-22759.
13. Hofbauer K, Schultz A, and Schultz JE (2008) Functional chimeras of the phosphodiesterase 5 and 10 tandem GAF domains. J Biol Chem 283:25164-25170.
14. Hofmann F, Bernhard D, Lukowski R, and Weinmeister P (2009) cGMP regulated protein kinases (cGK). Handb Exp Pharmacol 191:137-162.
15. Huai Q, Liu Y, Francis SH, Corbin JD, and Ke H (2004) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1- methylxanthine suggest a conformation determinant of inhibitor selectivity. J Biol Chem 279:13095-13101.
16. Kanacher T, Schultz A, Linder JU, and Schultz JE (2002) A GAF-domain-regulated adenylyl cyclase from Anabaena is a self-activating cAMP switch. EMBO J 21:3672-3680.
17. Martinez SE, Bruder S, Schultz A, Zheng N, Schultz JE, Beavo JA, and Linder JU (2005) Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: modes of ligand binding and dimerization. Proc Natl Acad Sci USA 102:3082-3087.
18. Martinez SE, Heikaus CC, Klevit RE, and Beavo JA (2008) The structure of the GAF A domain from phosphodiesterase 6C reveals determinants of cGMP binding, a conserved binding surface, and a large cGMP-dependent conformational change. J Biol Chem 283:25913-25919.
19. Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG, and Beavo JA (2002) The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci USA 99:13260-13265.
20. Moncada I, Jara J, Subirá D, Castaño I, and Hernández C (2004) Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 46:357-360; discussion 360-361.
21. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, and Koesling D (2003) Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 160:719-727.
22. Nichols DJ, Muirhead GJ, and Harness JA (2002) Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53 (Suppl 1):5S-12S.
23. Padma-Nathan H (2006) Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness. Int J Impot Res 18:423-431.
24. Rotella DP (2002) Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 1:674-682.
25. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, and Beavo JA (2002) Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 277:3310-3317.
26. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, and Beavo JA (2003) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22:469-478.
27. Sandner P, Hü tter J, Tinel H, Ziegelbauer K, and Bischoff E (2007) PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res 19:533-543.
28. Schlossmann J and Desch M (2009) cGK substrates. Handb Exp Pharmacol 191:163-193.
29. Schultz JE (2009) Structural and biochemical aspects of tandem GAF domains. Handb Exp Pharmacol 191:93-109.
30. Steidle CP, McCullough AR, Kaminetsky JC, Crowley AR, Siegel RL, Deriesthal H, and Tseng LJ (2007) Early sildenafil dose optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction. Int J Impot Res 19:154-160.
31. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, and Kass DA (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214-222.
32. Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, Bedja D, Gabrielson KL, Blanton R, Siderovski DP, et al. (2009) Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 119:408-420.
33. Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, Lin G, et al. (2006) Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 281:21469-21479.
34. Wilson LS, Elbatarny HS, Crawley SW, Bennett BM, and Maurice DH (2008) Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions. Proc Natl Acad Sci USA 105:13650-13655.
35. Zhang KY, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, et al. (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15:279-286.